Finance

Lists
4528:TYO
Ono Pharmaceutical Co Ltd
2 435,00 JPY
+1,52%
(+36,50) 1D
24 ივლ, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4528...
Open
2 397 JPY
High
2 440 JPY
Low
2 384 JPY
Mkt. cap
1,21 ტრლ.
Avg. vol.
1,45 მლნ.
Volume
1,51 მლნ.
Dividend
3,29%
Quarterly dividend
20 JPY
Ex-dividend date
29 სექ. 2025
P/E ratio
16,40
52-wk high
2 674 JPY
52-wk low
1 596 JPY
EPS
148 JPY
Shares outstanding
514,12 მლნ.
No. of employees
4 ათ.
Open
2 397 JPY
High
2 440 JPY
Low
2 384 JPY
Mkt. cap
1,21 ტრლ.
Avg. vol.
1,45 მლნ.
Volume
1,51 მლნ.
Dividend
3,29%
Quarterly dividend
20 JPY
Ex-dividend date
29 სექ. 2025
P/E ratio
16,40
52-wk high
2 674 JPY
52-wk low
1 596 JPY
EPS
148 JPY
Shares outstanding
514,12 მლნ.
No. of employees
4 ათ.
News stories
From sources across the web
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka. Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948. Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen. Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb. In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical Co Ltd
CEOGyo Sagara | Gyo Sagara
Employees4,21 ათ.
Founded1717
Headquartersოსაკა, Osaka, იაპონია
SectorPharmaceutical industry
Websiteono-pharma.com
Next call 7 დღეში
პარ, 31 ივლ, 01:00
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
- / 112,15 მლრ.
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
ივნ. 2025
სექ. 2025
დეკ. 2025
მარ. 2026
Revenue
127,54 მლრ.
129,60 მლრ.
139,90 მლრ.
118,75 მლრ.
Cost of goods sold
37,01 მლრდ.
34,96 მლრდ.
36,68 მლრდ.
33,06 მლრდ.
Cost of revenue
37,01 მლრდ.
34,96 მლრდ.
36,68 მლრდ.
33,06 მლრდ.
Research and development expenses
36,25 მლრდ.
34,77 მლრდ.
33,53 მლრდ.
42,49 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
31,09 მლრდ.
30,08 მლრდ.
31,73 მლრდ.
27,70 მლრდ.
Operating expense
68,53 მლრდ.
64,56 მლრდ.
67,00 მლრდ.
77,09 მლრდ.
Total operating expenses
105,54 მლრ.
99,53 მლრდ.
103,68 მლრ.
110,15 მლრ.
Operating income
22,00 მლრდ.
30,07 მლრდ.
36,22 მლრდ.
8,60 მლრდ.
Other non operating income
-
-
-
318,00 მლნ.
EBT including unusual items
22,65 მლრდ.
29,52 მლრდ.
37,20 მლრდ.
3,28 მლრდ.
EBT excluding unusual items
22,65 მლრდ.
29,52 მლრდ.
37,20 მლრდ.
8,77 მლრდ.
Income tax expense
5,02 მლრდ.
7,17 მლრდ.
8,31 მლრდ.
2,24 მლრდ.
Effective tax rate
22,16%
24,30%
22,35%
68,23%
Other operating expenses
1,19 მლრდ.
-291,00 მლნ.
1,73 მლრდ.
3,81 მლრდ.
Net income
17,67 მლრდ.
22,42 მლრდ.
28,86 მლრდ.
818,00 მლნ.
Net profit margin
13,86%
17,30%
20,63%
0,69%
Earnings per share
-
-
-
-
Interest and investment income
1,43 მლრდ.
677,00 მლნ.
1,39 მლრდ.
195,00 მლნ.
Interest expense
-773,00 მლნ.
-1,23 მლრდ.
-408,00 მლნ.
-34,00 მლნ.
Net interest expenses
655,00 მლნ.
-549,00 მლნ.
979,00 მლნ.
161,00 მლნ.
Depreciation and amortization charges
-
-
-
3,10 მლრდ.
EBITDA
31,23 მლრდ.
39,39 მლრდ.
45,82 მლრდ.
18,21 მლრდ.
Gain or loss from assets sale
-
-
-
2,20 მლრდ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer